109 results about "Hematological Tumor" patented technology

The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

The invention discloses an ROR1 specific chimeric antigen receptor and an application thereof. The ROR1 specific chimeric antigen receptor is a protein formed through serially connecting scFv of anti-human ROR1, the hinge region and the transmembrane region of CD8alpha, the transmembrane region and the intracellular region of CD28 and the intracellular region of CD3zeta from the amino end to the carboxyl end. T cells modified with the chimeric antigen receptor have a specific killing effect on tumor cells, and are expected to be in widely used in treatment of all kinds of solid tumor and blood tumors.

Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

The invention discloses application of an engineered T cell with an immune receptor for treatment of cancer. A chimeric antigen receptor consists of an extracellular signal peptide, an antigen bindingstructural domain, a first intracellular conduction structural domain and a second intracellular conduction structural domain and comprises the first intracellular conduction structural domain in theform of the immune receptor. The invention provides a plurality of amino acid sequences of the chimeric antigen receptor and provides the chimeric antigen receptor specific for CD19 malignant hematological tumors and CAR-T cells. In a blood tumor killing test, the ability of the CAR-T cells to kill tumor cells is significantly improved, and high safety and high antitumor activity are shown in clinical application.

The present invention provides a nucleic acid molecule encoding a chimeric antigen receptor targeting CD5, the chimeric antigen receptor comprises an extracellular domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular domain encoded by the chimeric antigen receptor comprises a CD5 binding domain which is an amino acid sequence as shown in SEQ ID NO:3. The chimeric antigen receptor comprises an extracellular domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular domain encoded by the chimeric antigenreceptor comprises a CD5 binding domain which is an amino acid sequence shown in SEQ ID NO:3. The cytokines secreted by NK cells were detected by flow cytometry, degranulation assay and ELISA. The results showed that the CD5 CAR NK cells had strong cytotoxic effect on hematological tumor cells expressing CD5, but had weak cytotoxic effect on cells not expressing CD5. The cytokines secreted by CD5CAR NK cells could effectively prevent the missed target effect. A chimeric antigen receptor CD5 scFv-CD8[alpha]-4-1BB-CD 3 Xi can be used in the treatment of lymphocytic hematologic tumors with positive CD 5.

Method and device for the in vitro analysis of mRNA of genes involved in hematological neoplasias. The device, composed of probes which specifically hybridize with genes involved in hematological neoplasias, designed so that its behaviour in the hybridization is similar, permits the evaluation of the mRNA level in biological samples taken from subjects suspected to be suffering from hematological neoplasia and facilitating the comparison between the different samples and their grouping by similarity in the gene expression patterns, especially when the probes are disposed in the form of microarray. The application of the method of the invention to obtain and process data of gene expression differences from the device of the invention permits the identification of genes significant for distinguishing samples associated to hematological neoplasias, facilitates the diagnosis of neoplasias as CLL and permits making a prognosis of the evolution thereof.

The present invention relates to cell cycle-dependent kinase (CDKs) degradation agents shown as a general formula (I), and/or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use of the derivatives, as pharmaceutically active agents, in medicines for preventing and/or treating diseases related to abnormal activity of CDKs. The compounds have good cell proliferation inhibiting effect on both solid tumors and hematological tumors, indicating that the compounds have potentials to treat related cancers and autoimmune diseases.

The invention discloses a construction method and an application of a recombinant gene of a bispecific chimeric antigen receptor for treating HIV infection complicated with blood tumor. The chimeric antigen receptor is formed by sequentially connecting a signal peptide, an HIV gp120 antigen specific single-chain antibody and an anti-CD19 single-chain antibody and then sequentially connecting witha CD28 transmembrane region, a CD28 intracellular structural domain (ICD), a 4-1BB costimulatory structural domain and a CD3zeta intracellular signal transduction structural domain in series, or the chimeric antigen receptor comprises: first CAR composed of the signal peptide, the chimeric antigen receptor, the HIV gp120 antigen specific single-chain antibody, the CD28 transmembrane region, the CD28-ICD, the anti-CD19 single-chain antibody, the CD8 transmembrane region, the CD28-ICD, the 4-1BB costimulatory structural domain and the CD3zeta intracellular signal transduction domain; and secondCAR composed of and the signal peptide, the anti-CD19 single-chain antibody, the CD8 transmembrane region in parallel, connecting the CD28-ICD, the 4-1BB costimulatory structural domain and the CD3zeta intracellular signal transduction domain, wherein the first CAR and the second CAR are sequentially connected in parallel.

The present invention provides an application of a zkscan3 gene or a protein modifier thereof in tumor therapy and particularly relates to a use of an inhibitor of the ZKSCAN3. The inhibitor of the ZKSCAN3 is used for preparation of a pharmaceutical composition promoting plasmocyte differentiation and proliferation, and/or treating tumors. The application provides a theoretical reference for a treatment strategy of selective knocking-out of the ZKSCAN3 in hematological tumors clinically, and has great significance for the clinical treatment of the hematological tumors targeting the ZKSCAN3.

The present invention discloses a MED12 gene mutation detecting kit and an application thereof. The kit comprises probe sets for detecting MED12 gene mutations and the probe sets consist of a probe 1to a probe 48. The kit can be used for detecting MED12 somatic mutations and germline mutations at a tumor genome level, can also be used for assistant diagnosis and minimal residual disease monitoring and prognosis evaluation, etc. of patients with hematological tumors, especially patients with acute myeloid leukemia. Besides, the kit is simple, sensitive and accurate in detection method and plays an important role in the field of medical detection

The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition or kit for the treatment of a disease treatable by activation of CD1d restricted T-cells, e.g. in autoimmune diseases, allergies, post-transplant conditions or infectious diseases, or in the treatment of a neoplastic disease, e.g. skin cancer, hematological tumors, colorectal carcinoma, and therapeutic compositions and kits therefor. Furthermore, the invention relates to methods of manipulating professional APCs and kits therefor.

The invention relates to the technical field of abdominal cavity drainage tube indwelling, and discloses abdominal cavity drainage tube indwelling equipment for hematologic tumor caring. The abdominalcavity drainage tube indwelling equipment comprises a box body, clamping pieces are movably connected to the two side walls in the box body correspondingly, pushing rods are slidably connected to theend, away from the box body, of the clamping pieces, piston blocks are slidably connected to the surfaces of the pushing rods, spring rods are movably connected to the ends, away from the pushing rods, of the piston blocks, an airflow groove is formed in the box body, and a drainage tube is fixedly connected to the end, away from the box body, of the airflow groove. When liquid flow exists on thesurface of a load bearing net, the generated pressure is the same as elastic force for overcoming shrinkage of the spring rods; when the drainage tube is blocked, the liquid flow cannot reach the surface of the load bearing net, thus the load bearing net does not provide force for overcoming shrinkage of the spring rods any more, the spring rods pull the piston blocks to shrink inwards, an air block belt is attracted to move under clamping of a limiting piece in the direction away from a fixing bag, released gas directly enters the drainage tube, and thus the effect that dredging can be conducted immediately when blockage occurs is achieved.

The invention discloses an antibody composition for detecting multiple myeloma minimal residual diseases, a kit and application, and belongs to the technical field of blood tumor treatment effect monitoring. According to the novel flow antibody combination scheme capable of being used for MRD monitoring of myeloma patients disclosed by the invention, CD319 or CD269 and other seven antibodies (CD138/CD38/CD184/CD27/CD19/CD56/ckappa/clamda) are combined to form a fixed combination of two groups of antibodies; through verification of 303 cases of myeloma patients, the antibody combination is feasible, accurate, convenient and fast, can be used for MRD monitoring after conventional chemotherapeutic drug treatment, and provides a good solution for the problem that MRD monitoring is difficult after DARA treatment.

The invention relates to the technical field of cerebrospinal fluid extraction for hematologic tumor patients, and discloses a cerebrospinal fluid extraction device for hematologic tumor patients. Thedevice comprises a strap, a flexible strap is movably connected to the surface of the strap, a positioning block is movably connected to the surface of the flexible strap, a clamping box is movably connected to the end, away from the strap, of the flexible strap through a connecting rod, a clamping ring is movably connected to the interior of the clamping box, an air bag is fixedly connected to the interior of the clamping ring, and a vent pipe is fixedly connected to the surface of the air bag. The step of moving an exhaust plate to a placing table is perforation positioning coarse adjustment, and a corrugated pipe is extruded to generate gas. As the placing table is only fixedly connected to the fourth from last positioning block, only the gas generated by the corrugated pipe connectedto the placing table can enter the exhaust plate through a telescopic rod. The gas flows to a chute to push out a push rod to push the placing table to move. In addition, perforation positioning fineadjustment and two-step adjustment are combined, so that the effect of improving puncture positioning accuracy is achieved.

The invention belongs to the field of pharmaceutical chemistry and relates to a 9,10-anthraquinone compound and a pharmaceutical application thereof, in particular to the 9,10-anthraquinone compound and the application thereof in the preparation of a phosphoglycerate mutase inhibitor and in the preparation of drugs for treating cancer. In particular, the invention discloses the application of the9,10-anthraquinone compound shown in the structure of a formula I, pharmaceutically-acceptable salts thereof, or a pharmaceutical composition taking the 9,10-anthraquinone compound as an effective active ingredient in preparing drugs for preventing and treating tumors. The compound can inhibit phosphoglycerate mutase activity and reduce cell metabolism level, and can be used for treating diseasessuch as solid tumors and blood tumors, and the tumors involved are pancreatic cancer, lung cancer, liver cancer, gastric cancer, esophageal cancer, intestinal cancer, breast cancer, cervical cancer, leukemia and melanoma.

The application of platelet microparticles in complications of elevated expression of leukemia cell tissue factors belongs to the field of biomedicine. In particular, the present invention discloses an application of platelet microparticles in preparation of agents for diagnosing or predicting elevated expression of cell tissue factors in a leukemia patient, and an application of an annexin V in preparation or screening of drugs for preventing or treating complications caused by elevated expression of cell tissue factors in a leukemia patient. The invention has an important value for assessment and timely treatment of malignant tumor patient patients, in particular to hematologic tumor patients in critical condition when applied in clinical practices.

The invention relates to the field of biomedical technologies and molecular biology, in particular to a peripheral blood miRNA marker combination and kit for diagnosing colon cancer and application of the peripheral blood miRNA marker combination and kit. The invention discloses a peripheral blood miRNA marker combination for colon cancer diagnosis. The miRNA marker combination comprises one or a combination of at least two of the following miRNAs: hsa-miR-1324, hsa-miR-20b-5p, hsa-miR-216b-5p, hsa-miR-367-5p, hsa-miR-597-5p and hsa-miR-934. The peripheral blood miRNA marker combination for colon cancer diagnosis is applied to preparation of a colon cancer detection reagent or tool. The peripheral blood miRNA tumor marker detection provided by the invention belongs to the field of liquid biopsy, has the characteristics of high specificity, earlier discovery, high sensitivity and minimal invasion compared with clinically conventional blood tumor markers, and is a novel marker for diagnosing various diseases including tumors. The detection result of the training set established by the invention on the test set shows that the diagnosis efficiency is as high as 95%, and the method has important significance for clinical colon cancer diagnosis in the future.

The invention discloses a blood tumor marker analysis device. The device comprises an analysis box, wherein a cover plate is hinged to a front wall of the analysis box, supporting rods which are symmetrically distributed are fixedly mounted at the top of the analysis box, a first fixing plate and a second fixing plate are fixedly mounted on the supporting rods, the first fixing plate is positionedbelow the second fixing plate, the supporting rods which are symmetrically distributed are fixedly mounted at the top of the analysis box, the first fixing plate and the second fixing plate can be conveniently limited and fixed, a liquid inlet pipe is fixedly mounted at the top of a stirring roller, the liquid inlet pipe can conveniently drive the stirring roller to rotate through a first bearing, a driven gear disc is fixedly mounted on a liquid inlet pipe, so s motor drives s driving gear disc to rotate conveniently, the driving gear disc drives s driven gear disc to rotate, the stirring roller can be made to rotate, the stirring roller can better stir blood tumor markers, and the blood tumor markers can be mixed more uniformly.

Provided is a chimeric antigen receptor, which comprises a co-stimulatory signal domain composed of an extracellular domain, a transmembrane domain and an intracellular domain, wherein the co-stimulatory signal domain comprises the full length or a fragment of the amino acids of encoded reverse dectin-1 and can treat multiple solid tumors and malignant hematological tumors.

The invention discloses a medical application of DNA methyltransferase inhibitor combined with anti-CD47 antibody for preparing antineoplastic drugs, which will be appreciated by those skilled in theart, CD47 in physiological state can maintain the immune tolerance of the body's own cells, and in pathological state, it can be overexpressed in a variety of hematological tumors and solid tumors, through the combination of phagocyte ligands to initiate a series of inhibitory signal transduction to avoid phagocytosis, and inhibit the presentation of tumor antigens phagocytes, anti-CD47 antibody has anti-tumor effect. However, anti-CD47 antibodies alone are expensive and have limited efficacy. DNA methyltransferase inhibitors play an anti-tumor role by restoring the activity of tumor suppressor genes. As that DNA methyltransferase inhibitor and the anti-CD47 antibody combine to exhibit obvious synergistic effect on anti-tumor, the DNA methyltransferase inhibitor and the anti-CD47 antibodycan be combined to be use for anti-tumor, thereby enhancing the anti-tumor effect of the anti-CD47 antibody and reducing the economic burden of the patient.

The invention discloses a nucleic acid molecule for coding a chimeric antigen receptor targeting CD123. The chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular signal transduction region; the extracellular region coded by the chimeric antigen receptor comprises a CD123 binding structural domain; the CD123 binding structural domain is an anti-CD123 single-chain antibody variable region fragment; and the anti-CD123 single-chain antibody variable region fragment is an amino acid sequence shown as SEQ ID NO.13 or a sequence with 90%-99% identity with the amino acid sequence shown as SEQ ID NO.13, an amino acid sequence shown as SEQ ID NO.14 or a sequence with 90%-99% identity with the amino acid sequence shown as SEQ ID NO.14, or an amino acid sequence shown as SEQ ID NO.15 or a sequence with 90%-99% identity with the amino acid sequence shown as SEQ ID NO.15. According to the nucleic acid molecule for coding the chimeric antigen receptor targeting the CD123, the chimeric antigen receptor can be used for treating CD123+ and/or CD33+ hematologic tumors, so that the off-target effect is effectively prevented, the treatment effect is better, and escape is not prone to occurring.

The invention discloses a baicalein derivative and a preparation method and application thereof. The general formula I of the baicalein derivative is as shown in the specification. In the formula, R1 is hydrogen, propargyl group, 2-propylamyl ester or methylenetriazole; and R2 is propargyl group or methylenetriazole. The compound can remarkably inhibit proliferation and survival of various hematological tumor cells such as leukemia cells and inhibit tumor cell signaling pathway at multiple targets so as to induce tumor cell apoptosis and achieve the effect of treating tumor diseases.